<乌鸦传媒>Upfront Systemic Therapy, Deferred Surgery Pass Muster in Advanced Kidney Cancer Two studies suggest no harm from deferred cytoreduction, potential benefits of immunotherapy May 02, 2023
<乌鸦传媒>CAR T-Cell Therapy Shows Promise in Advanced Kidney Cancer ORR of 30% in patients with CD70-positive disease using off-the-shelf, allogeneic product Apr 19, 2023
<乌鸦传媒>Post-Immunotherapy Combo Promising in Advanced RCC Duration of response reaches 18.6 months with belzutifan plus cabozantinib Apr 03, 2023
<乌鸦传媒>Novel PET Imaging Agent Accurately IDs Clear Cell Renal Cancers ZIRCON trial meets sensitivity and specificity targets Mar 13, 2023
<乌鸦传媒>Combo Falters in Papillary Renal Cancer, but Some Promise in MET-Driven Subset Over 50% of patients with advanced MET-driven tumors responded to savolitinib plus durvalumab Feb 24, 2023
<乌鸦传媒>ICI/TKI Combo Maintains Survival Benefit in Advanced RCC Updated trial data show nivolumab/cabozantinib doublet "is getting better with age" Feb 20, 2023
<乌鸦传媒>Pre-Op Axitinib Helps for Partial Nephrectomy of Complex Renal Tumors Approach in small ongoing trial resulted in reduction in tumor size and complexity Dec 02, 2022
<乌鸦传媒>Allogeneic CAR T-Cell Therapy Shows Early Promise in Kidney Cancer CTX130 yields sustained complete response in one patient with relapsed/refractory disease Nov 15, 2022
<乌鸦传媒>Role of Cytoreductive Nephrectomy Unclear for Dedifferentiated Kidney Cancer Thirteen-month survival gain falls short of statistical significance in observational study Nov 10, 2022
<乌鸦传媒>Immune Stimulator May Enhance Targeted Therapy's Activity in Metastatic RCC Numerical advantage in median survival, response rate, durability with dendritic-cell agent Nov 09, 2022
<乌鸦传媒>Immunotherapy Doublet Shows Promise for Nonsurgical Control of Small Kidney Cancers Nivolumab/ipilimumab achieves 1-year PFS of 100% in unresectable T1N0M0 tumors Nov 07, 2022
<乌鸦传媒>Probiotic May Rev Up Response to Immunotherapy in Advanced Kidney Cancer Dramatic slowing of disease progression, prolonged responses with microbiome modulator Nov 06, 2022
<乌鸦传媒>Triplet in First-Line Kidney Cancer Thwarts Disease Progression Randomized study shows "clinically meaningful" PFS improvement over dual immunotherapy alone Sep 13, 2022
<乌鸦传媒>Three Adjuvant Immunotherapy Trials Flop in Renal Cell Carcinoma Studies appear to contradict benefit previously shown with pembrolizumab in this setting Sep 12, 2022
<乌鸦传媒>Fewer Complications With Robotic Nephrectomy in Complex Kidney Tumors However, trial comparing robotic and open surgery was stopped early due to low enrollment Jul 06, 2022
<乌鸦传媒>Oral Retinoid May Ease Painful Skin Reactions to Anticancer Therapy Preliminary data on acitretin therapy are promising May 11, 2022
<乌鸦传媒>Check Troponin in RCC Patients Before Checkpoint-VEGFR Inhibitor Combo In JAVELIN Renal 101, those with high levels had more heart events with avelumab-axitinib Mar 05, 2022
<乌鸦传媒>FDA OKs PD-1 Inhibitor for Adjuvant Treatment of Kidney Cancer Key trial showed 32% reduction in risk of recurrence with pembrolizumab Nov 18, 2021
<乌鸦传媒>Cabozantinib Shows Activity Against RCC Brain Metastases Retrospective study reported intracranial responses in about one half of patients Oct 22, 2021
<乌鸦传媒>'A Quantum Leap Forward': Potential New Standard in High-Risk RCC Adjuvant immunotherapy led to 32% reduction in the risk of recurrence, positive trend in OS Jun 03, 2021
<乌鸦传媒>How Did a Patient Survive a Decade With Metastatic RCC? Surgery had beneficial role May 17, 2021
<乌鸦传媒>A CLEAR Upfront Winner in Advanced RCC? Pembrolizumab-lenvatinib makes splash with longest PFS benefit in RCC recorded to date Feb 14, 2021
<乌鸦传媒>Practice-Changing Trial in Metastatic Papillary RCC Cabozantinib improved PFS, response rates over sunitinib Feb 14, 2021
<乌鸦传媒>Another First-Line Combo Succeeds in Advanced RCC Third immunotherapy plus TKI combination tops sunitinib Sep 19, 2020
<乌鸦传媒>Olympic Ice Dancer's Renal Cell Carcinoma Maia Shibutani is "embracing the moment" and raising money for healthcare workers Sep 10, 2020
<乌鸦传媒>Cancer Immunotherapy Tied to Severe COVID-19 Outcomes Nearly threefold increased risk of hospitalization, severe respiratory illness Jun 25, 2020
<乌鸦传媒>6-Week Keytruda Safe, Effective in Melanoma Schedule gets FDA approval for all adult indications Apr 30, 2020
<乌鸦传媒>DOAC Works in Cancer-Related VTE, No Tradeoff in Bleeds Apixaban monotherapy matches dalteparin in non-inferiority trial Mar 29, 2020
<乌鸦传媒>Are Low-Density Incidental Renal Masses Being Misdiagnosed? New study raises concerns about criteria for benign cysts vs aggressive renal cancer Dec 23, 2019
<乌鸦传媒>Metastatic Renal Cell Carcinoma: Watch for Brain Mets Present in roughly 5% of patients, survival worse in patients with larger or more lesions Nov 18, 2019
<乌鸦传媒>Long-Term Surveillance Safe for Small Renal Tumors Two cases of metastasis, one cancer death after almost 5 years of follow-up Jun 13, 2019
<乌鸦传媒>Surgery Delay OK for Most With Renal Cell Carcinoma Two studies add support for active surveillance for small tumors May 08, 2019
<乌鸦传媒>Do Keloids Convey a Higher Cancer Risk? Taiwanese researchers show association between raised scars and cancers Mar 03, 2019
<乌鸦传媒>No Survival Bump Yet with Tivozanib for RCC Selected studies on kidney cancer from the Genitourinary Cancers Symposium Feb 18, 2019
<乌鸦传媒>Will Biomarkers Eventually Replace Physicians? Milton Packer imagines the end of nonprocedural medicine as we know it Jan 16, 2019
<乌鸦传媒>Kidney Stones Tied to Renal Carcinoma But more research is needed to unravel mechanisms behind the relationships, study authors say Dec 20, 2018
<乌鸦传媒>SABR Equally Effective in RCC Patients With One or Both Kidneys Minimal side effects reported with high-dose treatment Oct 23, 2018
<乌鸦传媒>Combination Slows Advanced RCC Avelumab-axitinib beneficial, irrespective of PD-L1 status Oct 23, 2018
<乌鸦传媒>Morning Break: Human Side of Addiction; Eyeing Da Vinci's Genius; No CV Indication for Ilaris Health news and commentary from around the Web gathered by the 乌鸦传媒 staff Oct 19, 2018
<乌鸦传媒>Many with Metastatic Kidney Cancer Can Skip Surgery Overall survival with single-agent sunitinib better than with resection Jun 04, 2018
